Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739973 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,694
- Enrollment target
NCT00739973 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,694 participants.
The verdict
NCT00739973, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,694 participants
- Enrollment target
Study Summary
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
Interventions
- DRUG Placebo
- DRUG Aliskiren 150 mg tablet
- DRUG Aliskiren 300 mg tablet
- DRUG Amlodipine 5 mg capsule
- DRUG Amlodipine 10 mg capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,694 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739973
The ClinicalTrials.gov registry entry for NCT00739973 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,694 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00739973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739973 about?
NCT00739973 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension". Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
What is the current status of trial NCT00739973?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,694 participants. The study started on 2008-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00739973?
The interventions under investigation include: Placebo (DRUG), Aliskiren 150 mg tablet (DRUG), Aliskiren 300 mg tablet (DRUG), Amlodipine 5 mg capsule (DRUG), Amlodipine 10 mg capsule (DRUG).
Who is sponsoring clinical trial NCT00739973?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.